As per attachment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Norris Medicines Ltd reported audited financial results for Q4 and FY ended March 2026. Revenue from operations grew 39.7% to Rs 813.20 Lakhs from Rs 582.02 Lakhs in FY25. The company narrowed its net loss significantly from Rs 123.75 Lakhs to Rs 28.06 Lakhs year-on-year. However, the company continues to have negative net worth with total equity at negative Rs 1,514.80 Lakhs. The auditors issued an unmodified (clean) opinion, and a new internal auditor M/s. Dhiren Y Parikh & Co. was appointed for FY 2026-27. No related party transactions were reported for H2 FY26.
While the company showed improvement in reducing losses and growing revenue, the persistent negative equity (net worth) raises going concern doubts. Shareholders should monitor whether the company can return to profitability and restore positive net worth.